Efficacy and safety of immune checkpoint inhibitor without pemetrexed for first-line maintenance therapy in advanced lung adenocarcinoma.

person Ming Gao Department of medical oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China info_outline Ming Gao, Wenyu Yang, Chunyu Wang, Ting Wang, Fangfang Jing, Fan Zhang, Haitao Tao, Junxun Ma, Yi Hu, Lijie Wang

Authors person Ming Gao Department of medical oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China info_outline Ming Gao, Wenyu Yang, Chunyu Wang, Ting Wang, Fangfang Jing, Fan Zhang, Haitao Tao, Junxun Ma, Yi Hu, Lijie Wang Organizations Department of medical oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China, School of Medicine, Nankai University, Tianjin, China, The First Medical Center of PLA General Hospital, Beijing, China, School of Medicine, Nankai University, Beijing, China, Department of Oncology, the First Medical Center, Chinese PLA General Hospital, Beijing, China., Beijing, China, Department of Medical Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, China, Department of medical oncology, The First Medical Center of PLA General Hospital, Beijing, China, The Fifth Medical Center of PLA General Hospital, Beijing, China Abstract Disclosures Research Funding No funding received None. Background: Currently, the standard first-line treatment for driver gene-negative advanced lung adenocarcinoma (LUAD) is chemotherapy plus immune checkpoint inhibitor (ICI) therapy followed by pemetrexed and ICI. However, pemetrexed is prone to certain adverse reactions and needs to be pretreated. At present, there is no relevant study on the efficacy between pemetrexed combined with ICI and ICI monotherapy in maintenance treatment. The object of this study is to explore the efficacy and safety of ICI as maintenance therapy in such patients. Methods: The study retrospectively analyzed patients with driver gene-negative advanced LUAD in PLA General Hospital from January 2019 to June 2022. These patients had received pemetrexed and platinum-based chemotherapy combined with ICI for 4-6 cycles. Patients who didn’t progress were subsequently entered into maintenance stage. The primary endpoint was progression-free survival (PFS) and overall survival (OS), and the secondary endpoint was objective response rate (ORR) and safety. Results: A total of 93 patients with advanced LUAD who received first-line chemotherapy combined with ICI were collected, including 39 patients receiving pemetrexed plus ICI of maintenance therapy, 30 patients receiving ICI maintenance therapy, and 24 patients who failed to enter the maintenance treatment. Baseline characteristics of ICI group and pemetrexed plus ICI group were as follows: median age, 61.5 (42~81) years vs. 63 (35~74) years; male, 66.7% (20/30) vs. 79.5% (31/39); Smoking history, 63.3% (19/30) vs. 74.4% (29/39); Brain metastases, 10% (3/30) vs. 23.1% (9/39). ORR was 60.0% (95%CI 42.5-77.5) in the ICI monotherapy group and 69.2% (95%CI 54.7~83.7) in the pemetrexed plus ICI group. By November 30, 2022, the median follow-up time was 19.2 months. The median PFS of the two groups were 15.8 months (95%CI 9.84-21.70) in ICI group and 22.8 months (95%CI 4.57-40.97) in pemetrexed plus ICI group and there was no statistical difference between the two groups (P = 0.50). Neither group achieved OS. The incidence of all grade treatment-related adverse events (TRAEs) was 90.0% (27/30) in ICI monotherapy group and 92.3% (36/39) in pemetrexed plus ICI group. Grade 3/4 TRAEs occurred in 23.3% (7/30) and 23.1% (9/39) of each cohort and no grade 5 TRAE occurred. Conclusions: ICI maintenance therapy without pemetrexed showed great therapeutic efficacy in first-line maintenance stage and can be a feasible regimen in advanced lung adenocarcinoma.